Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2020-02-27
2023-02-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation
NCT02464735
Impact of Sleep Quality on Respiratory Function and Weaning of Mechanical Ventilation
NCT02920281
Impact of Humidification on Sleep Quality During Home Non Invasive Ventilation
NCT03561974
Determination of the Optimal Spontaneous Breathing Trial During Weaning of Mechanical Ventilation
NCT04222569
Sleep Quality in Intensive Care Unit Patients at High Risk of Extubation Failure
NCT02911506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
One arm with Gamma-OH® treatment
Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
Gamma Hydroxybutyrate
Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gamma Hydroxybutyrate
Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* difficult weaning from mechanical ventilation according to international guidelines, i.e. who failed at least one spontaneous breathing trial.
* Patients will be included after to obtain inform consent.
Exclusion Criteria
* central nervous disease
* psychiatric disease
* severe obesity
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Poitiers
Poitiers, Poitiers, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GO-SLEEP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.